Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 6, 2010, Pages 1023-1025

  Han, Kwang Hyub ^a   Park, Jun Yong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; INTERFERON; LAPATINIB; MITOMYCIN; PLACEBO; SORAFENIB; SUNITINIB; TEGAFUR; URACIL; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG TARGETING; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; SYSTEMIC THERAPY; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION ROUTE; LIVER NEOPLASMS; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION ROUTES; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 77952988042     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06359.x     Document Type: Editorial

References (22)

1. Parkin DM, Bray F, Ferlay Pisani P. Global cancer statistics 2002. CA Cancer J. Clin. 2005 55 : 74 108.
2. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006 11 : 790 800.
3. Han KH, Lee JT, Seong J. Treatment of non-resectable hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2002 17 : S424 7.
4. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol. 2005 23 : 2892 2899.
5. Han KH, Park JY. Chemotherapy for advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008 23 : 682 684.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
7. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma. A systematic review of randomized controlled trial. Ann. Oncol. 1997 8 : 117 136.
8. Patt YZ, Yoffe B, Charnsangavej C et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferonalpha-2b. Cancer 1993 72 : 2574 2582.
9. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-a and intra-arterial 5-fluorouracil: role of type I interferon receptor expression. Br. J. Cancer 2005 93 : 557 564.
10. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006 106 : 1990 1997.
11. Park JY, Ahn SH, Yoon YJ et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007 110 : 129 137.
12. Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002 95 : 588 595.
13. Chaudhuri NK, Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations. J. Biol. Chem. 1959 234 : 1255 1262.
14. Hertzog PJ, Hwang SY, Kola I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev. 1994 39 : 226 232.
15. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000 31 : 54 8.
16. Oie S, Ono M, Yano H et al. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliperative effect by 6-fluorouracil and interferon-α. Int. J. Oncol. 2006 29 : 1469 1478.
17. Wada H, Nagno H, Yamamoto H et al. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 2009 9 : 361 373.
18. Katamura Y, Aikata H, Kimura Y et al. Intra-arterial 5-fluorouracil/ interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J. Gastroenterol. Hepatol. 2010 25 : 1117 1122.
19. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008 359 : 378 390.
20. Cheng A-L, Kang Y-K, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 10 : 25 34.
21. Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008 113 : 995 1003.
22. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009 69 : 223 240.